Fig. 2From: 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancerOverall survival by PET metabolic response among patients in the nab-paclitaxel 125 mg/m2 cohort. CMR, complete metabolic response; OS, overall survival; PET, positron emission tomography; PMR, partial metabolic responseBack to article page